Abstract
The optimal time to initiate antiretroviral therapy (ART) in patients presenting with HIV-associated tuberculosis has been a controversial issue. Early initiation of ART may be complicated by high pill burden, overlapping drug toxicities, and an increased risk of immune reconstitution inflammatory syndrome. Delayed initiation of ART may result in progressive immune decline, HIV-associated complications and death. Retrospective studies of HIV/TB coinfected patients suggested that initiation of ART during TB treatment might be beneficial. Emerging evidence from recent randomised controlled trials supports early ART initiation in HIV/TB patients with advanced immunosuppression, apart from those presenting with tuberculous meningitis. However, current guidelines for antiretroviral therapy vary in their recommendations for timing of ART initiation in HIV-associated TB.
Keywords: Antiretroviral therapy, HIV, initiation, timing, tuberculosis, when to start.
Current Respiratory Medicine Reviews
Title:When to Start Antiretroviral Therapy in HIV-Associated Tuberculosis
Volume: 9 Issue: 3
Author(s): Mili E. Torok
Affiliation:
Keywords: Antiretroviral therapy, HIV, initiation, timing, tuberculosis, when to start.
Abstract: The optimal time to initiate antiretroviral therapy (ART) in patients presenting with HIV-associated tuberculosis has been a controversial issue. Early initiation of ART may be complicated by high pill burden, overlapping drug toxicities, and an increased risk of immune reconstitution inflammatory syndrome. Delayed initiation of ART may result in progressive immune decline, HIV-associated complications and death. Retrospective studies of HIV/TB coinfected patients suggested that initiation of ART during TB treatment might be beneficial. Emerging evidence from recent randomised controlled trials supports early ART initiation in HIV/TB patients with advanced immunosuppression, apart from those presenting with tuberculous meningitis. However, current guidelines for antiretroviral therapy vary in their recommendations for timing of ART initiation in HIV-associated TB.
Export Options
About this article
Cite this article as:
Torok E. Mili, When to Start Antiretroviral Therapy in HIV-Associated Tuberculosis, Current Respiratory Medicine Reviews 2013; 9 (3) . https://dx.doi.org/10.2174/1573398X113099990016
DOI https://dx.doi.org/10.2174/1573398X113099990016 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Reactions of Hydrazones with Lead Tetraacetate in Organic Synthesis
Current Organic Chemistry Chronic Cerebral Hypoperfusion Protects Against Acute Focal Ischemia,Improves Motor Function, and Results in Vascular Remodeling
Current Neurovascular Research Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
Current Pharmaceutical Design Mitochondria: The Common Upstream Driver of Amyloid-β and Tau Pathology in Alzheimers Disease
Current Alzheimer Research Peroxisome Proliferator-Activated Receptor-γ and Its Ligands in the Treatment of Tumors in the Nervous System
Current Stem Cell Research & Therapy Biochemical Markers in CSF of ALS Patients
Current Medicinal Chemistry Topical Delivery of Drugs for the Effective Treatment of Fungal Infections of Skin
Current Pharmaceutical Design Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy
Current Drug Discovery Technologies Neuropathological Correlates of Cerebral Multimorbidity
Current Alzheimer Research Prevalence and Resistance Profiles of Vancomycin-resistant Enterococcal Isolates in Iran; An Eight-month Report from Nine Major Cities
Infectious Disorders - Drug Targets Recent Advances in Nanoneurology for Drug Delivery to the Brain
Current Nanoscience Endocarditis Due to Salmonella Enterica Subsp. Arizonae in a Patient with Sickle Cell Disease: A Case Report and Review of the Literature
Cardiovascular & Hematological Disorders-Drug Targets Olfactory Ensheathing Cells Protect Cortical Neuron Cultures Exposed to Hypoxia
CNS & Neurological Disorders - Drug Targets Does the Development of Vaccines Advance Solutions for Tuberculosis?
Current Molecular Pharmacology Is there a Rational Approach for Increasing Drug Specificity? Considerations on CNS Target Choice and Validation
Recent Patents on CNS Drug Discovery (Discontinued) GqPCR-mediated Signalling in the Spotlight: From Visualization Towards Dissection and Quantification
Current Pharmaceutical Biotechnology A Hyperlipidemic Diet Induces Structural Changes in Cerebral Blood Vessels
Current Neurovascular Research Drug Discovery in Enteroviral Infections
Infectious Disorders - Drug Targets FDG-PET Scan in Sarcoidosis: Clinical and Imaging Indications
Current Medical Imaging Effects of Cholinesterase Inhibitors on the Activities and Protein Levels of Cholinesterases in the Cerebrospinal Fluid of Patients with Alzheimers Disease: A Review of Recent Clinical Studies
Current Alzheimer Research